Latest news and press releases about Surrozen, Inc. (SRZN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Price
| Price | $16.93 |
| Market Cap | $127M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -0.90 |
| EV / EBITDA | -0.22 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 187.62% |
| Return on Invested Capital | -40.84% |
| Return on Assets | -287.29% |
| Gross Margin | 99.44% |
| Operating Margin | -385.28% |
| Net Margin | -2885.33% |
Related companies: AGEN · ATOS · CGTX · GLSI · IMMX · IRD · SEER
Explore sector: Healthcare · Biotechnology
More sections of SRZN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks